Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169


Associations between diabetes medication use and risk of second breast cancer events and mortality.

Calip GS, Yu O, Hoskins KF, Boudreau DM.

Cancer Causes Control. 2015 Aug;26(8):1065-77. doi: 10.1007/s10552-015-0599-z. Epub 2015 May 9.


Metabolic syndrome and outcomes following early-stage breast cancer.

Calip GS, Malone KE, Gralow JR, Stergachis A, Hubbard RA, Boudreau DM.

Breast Cancer Res Treat. 2014 Nov;148(2):363-77. doi: 10.1007/s10549-014-3157-6. Epub 2014 Oct 10.


Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.

Calip GS, Yu O, Elmore JG, Boudreau DM.

Cancer Causes Control. 2016 May;27(5):709-20. doi: 10.1007/s10552-016-0744-3. Epub 2016 Apr 6.


Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS.

Breast Cancer Res Treat. 2014 Apr;144(2):405-16. doi: 10.1007/s10549-014-2870-5. Epub 2014 Feb 21.


Frequent antibiotic use and second breast cancer events.

Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1588-99. doi: 10.1158/1055-9965.EPI-13-0454. Epub 2013 Jul 5.


Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis.

Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI.

Cancer Res. 2017 Nov 1;77(21):6033-6041. doi: 10.1158/0008-5472.CAN-17-0687. Epub 2017 Sep 21.


Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.

Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK.

JAMA Intern Med. 2014 Dec;174(12):1955-62. doi: 10.1001/jamainternmed.2014.5294.


Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.


Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.

Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, Shariat SF.

Urol Oncol. 2014 Jan;32(1):49.e7-14. doi: 10.1016/j.urolonc.2013.07.006. Epub 2013 Oct 17.


Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.

Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR.

JAMA. 2014 Jun 11;311(22):2288-96. doi: 10.1001/jama.2014.4312.


Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.

Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1603-1610. doi: 10.1158/1055-9965.EPI-17-0346. Epub 2017 Aug 14.


Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A.

Scand J Urol. 2017 Feb;51(1):5-12. doi: 10.1080/21681805.2016.1271353. Epub 2017 Jan 13.


Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women.

Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM.

Cancer Causes Control. 2012 Nov;23(11):1785-95. doi: 10.1007/s10552-012-0057-0. Epub 2012 Sep 13.


Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.

Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr DS, Shariat SF.

BJU Int. 2013 Dec;112(8):1105-12. doi: 10.1111/bju.12448.


Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus.

Chang YL, Sheu WH, Lin SY, Liou WS.

Clin Exp Med. 2018 Aug;18(3):383-390. doi: 10.1007/s10238-018-0497-2. Epub 2018 Mar 23.


No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.

Kowall B, Stang A, Rathmann W, Kostev K.

Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):865-74. doi: 10.1002/pds.3823. Epub 2015 Jul 1.


The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.

Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA.

Cancer Med. 2014 Aug;3(4):1025-34. doi: 10.1002/cam4.259. Epub 2014 Jun 18.


Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP.

Diabetes Care. 2014 Sep;37(9):2522-32. doi: 10.2337/dc14-0584. Epub 2014 Jun 4.


Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer.

Baglia ML, Cui Y, Zheng T, Yang G, Li H, You M, Xu L, Murff H, Gao YT, Zheng W, Xiang YB, Shu XO.

Cancer Res Treat. 2019 Apr;51(2):538-546. doi: 10.4143/crt.2017.591. Epub 2018 Jul 2.

Supplemental Content

Support Center